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Abstract
The 18q21 region is frequently altered in gastrointestinal tumors. Three candidate tumor suppressor genes have been
identified in it : DCC, Smad4/DPC4 and Smad2 ; the mechanisms involving their inactivation have not been completely
elucidated. In this study, genetic losses at 18q21 and expression of DCC and DPC4 in colorectal (n = 12) and pancreatic
(n = 16) cell lines and in colorectal tissues (n = 10) were analyzed. The status of the 18q21 region was assessed using
microsatellite analysis and duplex PCR of exonic sequences; expression was analyzed by RT-PCR; mutational analysis of
DPC4 cDNA was performed in selected cases. Homozygous losses of microsatellite markers at 18q21 were not observed in
colon or pancreas lines; however, a higher proportion of apparent homozygosity than expected was found. DCC and DPC4
transcripts were detected in 11/12 and 12/12 colorectal cancer lines, respectively. In tumors, homozygous losses at 18q21 were
detected in three cases, without affecting DCC. All tumors retained DCC and DPC4 mRNA expression. In pancreatic lines,
DPC4 was inactivated through homozygous deletion (n = 5), intragenic mutation (n = 3), and lack of protein (n = 2). In
conclusion: (1) microsatellite analysis does not provide adequate information regarding homozygous losses at 18q21;
(2) approximately 65% of pancreas cancer lines show inactivation of DPC4 ; and (3) loss of DCC and DPC4 occur
independently. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Loss of heterozygosity (LOH) at 18q21 in colorec-
tal tumors suggested the presence of tumor suppres-
sor gene(s) [1] and alterations in this region have
been reported in numerous types of human tumors,
specially those of the gastrointestinal tract [2^5].
Much interest in this region arose because early re-
ports indicated that 18q losses occur at late stages of
the multistep colorectal carcinogenesis and are asso-
ciated with high metastatic potential and reduced
patient survival [6^8]. Some of these studies analyzed
the 18q21 region together with other genetic altera-
tions [1,2,6] ; more recent work has analyzed the
18q21 region alone [9^12]. Nonetheless, the status
of chromosome 18q as a prognostic factor in colo-
rectal tumors is still a subject of much controversy
[13]. Most commonly, this genetic region has been
analyzed using microsatellite markers [9^12,14,15]
as a surrogate for the direct study of genes of interest
because the latter is hampered by the presence of
normal cells in tumor tissues. However, there is a
need to carefully establish whether the results of mi-
crosatellite analysis can be used to assess gene loss.
Fearon et al. [16] identi¢ed a putative tumor sup-
pressor gene localized to 18q21, designated DCC for
deleted in colorectal cancer. The DCC gene contains
29 exons and encodes a membrane glycoprotein of
the Ig superfamily that has been proposed to be in-
volved in cell di¡erentiation in some studies [17].
Because of the complexity of this gene, few in depth
molecular studies have been performed. More re-
cently, the DCC protein was described as a Netrin-
1 receptor, implicated in axon guidance during the
development of nervous system [18], and as an in-
ducer of apoptosis [19]. Nevertheless, the actual role
of DCC in intestinal di¡erentiation and/or tumori-
genesis is not clear on the basis of both in vitro
studies [20] and gene inactivation in transgenic mice
[21]. Because of the controversial evidences on the
role of DCC in cancer and because loss of DCC
could not account for all the ¢ndings in allelotype
studies, additional genetic analysis of the 18q21 re-
gion led to the identi¢cation of two other genes:
DPC4 or Smad4 [22], and JV18-1 or Smad2 [23].
These genes encode intracellular transducers involved
in signalling by members of the TGF-L family of
ligands [24]. DPC4 has been reported to be inacti-
vated in up to 60% of pancreatic cancers [22,25], but
rarely in colorectal cancers [14,26]). Smad2 appears
to be mutated in less than 10% of colorectal tumors
[23,27,28]. Loss or reduction in mRNA levels of
DCC, DPC4 and Smad2 was found frequently asso-
ciated to allelic losses for all three genes in tumor
samples and cancer cell lines [16,25,29].
In the course of a study on the expression of DCC
in colon cancer cell lines, we found detectable levels
of DCC transcripts in the majority of the cell lines
analyzed [20]. Therefore, the implication of this in-
teresting chromosomal region looks more complex
than initially thought and requires more detailed
studies to evaluate the participation of each of these
genes. The ¢ndings described above prompted us to
examine the status of DCC and DPC4 genes and
mRNAs in colorectal and pancreatic tumors. To
this aim, we have used a panel of colorectal cancer
cell lines (n = 12), colorectal tumors and their corre-
sponding normal tissue (n = 10), and pancreas cancer
cell lines (n = 16) to analyze: (1) genetic losses at
18q21 using microsatellite markers and duplex PCR
with exonic primers for DCC, DPC4, and L-actin ;
(2) mRNA expression of DCC and DPC4; and
(3) mutations in exons 8^11 of DPC4 cDNA in pan-
creas cancer lines.
2. Materials and methods
2.1. Cell lines
Caco-2, HT-29, and HT-29-derived cell lines, se-
lected with 1036 methotrexate (M6) or 1033 metho-
trexate (M3) [30], were provided by Drs. T. Lesuf-
£eur and A. Zweibaum (INSERM U505, Paris,
France); SK-CO-1 and -20 were obtained from Dr.
L.J. Old (Ludwig Institute for Cancer Research, New
York Branch, New York, NY); SW480, SW620,
SW1116, SW1417, HRT-18, and LS174T colon cell
lines, and Capan-1, Capan-2, Hs766T, RWP-1,
RWP-2, MIA PaCa-2, AsPC-1, and HPAF pancreas
cancer cell lines were purchased from the ATCC
(Rockville, MD). IMIM-PC-1, IMIM-PC-2, SK-
PC-1, and SK-PC-3 were obtained in our laboratory
[31]. MZPC-1, MZPC-2, and MZPC-4 were provided
by Dr. A. Knuth (Nordwestern Krankenhaus,
Frankfurt, Germany). CFPAC-1 cells were provided
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by Dr. R. Frizzel (University of Alabama, Birming-
ham, AL) [32]. Normal exocrine pancreas cultures
were obtained as described elsewhere [33]; all cells
in these cultures display phenotypical and functional
properties of normal ductal cells [33,34]. Cells were
grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) (Gibco, Glasgow, UK) in a humidi¢ed atmos-
phere of 5% CO2, 95% air. Cancer cells were seeded
at a density such that con£uence was reached at days
5^7, and were maintained in culture until 10 days
after con£uence. Culture medium was changed every
other day to avoid nutrient depletion.
2.2. Tissue samples
Surgical specimens (n = 10) were collected from pa-
tients undergoing elective large bowel resection for
colorectal carcinoma at Hospital del Mar, Barcelona,
Spain. Patients’ age ranged from 46 to 98 years;
there were eight men and two women. Seven cases
had a colonic tumor and three cases had a rectal
tumor. The distribution of the cases by stage was
as follows: stage II (n = 4), stage III (n = 4), and stage
IV (n = 2). Fresh samples of normal mucosa distant
from tumor (v8 cm) and tumor were ¢xed with 4%
neutral bu¡ered formaldehyde, embedded in para⁄n,
and used for DNA isolation and subsequent micro-
satellite analysis. An adjacent sample of each type of
tissue was snap frozen in liquid nitrogen for RNA
extraction.
2.3. DNA and RNA isolation
DNA from cultured cells was isolated by the salt-
ing out procedure [35]. Genomic DNA from normal
and neoplastic colon was obtained by microdissec-
tion of 5-Wm-thick sections of formalin-¢xed, para⁄n
embedded tissues. The ¢rst section was stained with
hematoxylin and eosin and the percentage of tumor
cells was estimated by visual examination under
microscope. Microdissected areas contained at least
80% malignant cells. The tissue samples were scraped
with a scalpel, depara⁄nized with xylene, washed in
100% ethanol, and air dried. Tissue pellets were re-
suspended in digestion bu¡er (10 mM Tris^HCl pH
9.0, 50 mM KCl, 1% Triton X-100) containing 0.8
mg/ml of proteinase K (Sigma), and incubated over-
night at 55‡C. The proteinase K was inactivated by
incubating at 95‡C for 10 min. Digested products
were centrifuged and the supernatant was used for
PCR. RNA from cultured cells and tissues was iso-
lated using the guanidinium isothiocyanate method.
2.4. Microsatellite analysis
LOH studies were performed by PCR ampli¢ca-
tion of four highly polymorphic microsatellite
markers from region 18q21.1. D18S877 is centromer-
ic to DPC4, D18S851 is located between DPC4 and
DCC, D18S858 and D18S64 are telomeric to DCC
gene. These microsatellite markers have been de-
scribed previously [14]. Primer pairs were obtained
commercially from MapPairs (Research Genetics,
Huntsville, AL). PCR ampli¢cation was performed
in 50 Wl reaction volume, containing approximately
100 ng genomic DNA, 50 pmol primers, 200 WM
dNTPs, 2 mM MgCl2, 5 Wl of 10U PCR bu¡er
(Promega, Madison, WI) and 1.25 units of Taq
DNA polymerase (Promega). PCR conditions were
as follows: after an initial step of denaturation (94‡C
for 5 min), a total of 35 or 45 ampli¢cation cycles
were carried out with cultured cell DNA or tissue
DNA, respectively. Each cycle consisted of denatur-
ation at 94‡C for 40 s, annealing at 57^61‡C for 30 s,
depending on primer pair used, and extension at
72‡C for 30 s, followed by 2 min at 55‡C and a ¢nal
elongation step of 5 min at 72‡C. An aliquot (5 Wl) of
the ampli¢cation products was mixed with 2 Wl of
loading bu¡er (98% formamide, 10 mM EDTA,
0.025% bromophenol blue, 0.025% xylene cyanol),
denatured at 90‡C for 10 min, and electrophoresed
in a 6% denaturing polyacrylamide sequencing gel
containing 7 M urea at 45 W for 2^3 h. Before load-
ing, the gel was pre-run for 40 min at 45 W. After
electrophoresis, the gel was stained using silver ni-
trate (Sigma). LOH in cultured cells for which cor-
responding normal DNA was not available was esti-
mated by comparing the heterozygosity frequency
observed in the cell line panel used with that de-
scribed in the normal population for each microsa-
tellite marker. LOH analysis of colorectal cancer tis-
sues was performed by comparing the ampli¢cation
products obtained from normal and tumor DNA. If
one allele was estimated as decreased in tumor rela-
tive to normal DNA by three independent observers,
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the case was scored as LOH. Homozygous deletions
were de¢ned as lack of detectable PCR products us-
ing genomic DNA whose quality had been appropri-
ately tested.
2.5. Duplex PCR on genomic DNA
PCR ampli¢cation on genomic DNA was per-
formed in 25 Wl reaction volume, containing 0.2
WM of each primer, 200 WM dNTPs, 2 mM MgCl2,
1U PCR bu¡er (Promega, Madison, WI), 1.25 units
of Taq polymerase (Promega), and 100 ng genomic
DNA. Duplex PCR for DCC gene was done using
primers EX1S (5P-CCCAGACTAACTGCATCAT-
CATGAG-3P) and EX3AS (5P-CCTCTCAATG-
GAATAATATCGCTGC-3P), located within exon
15 of the DCC gene, and primers ACT1S (5P-ATG-
TACGTTGCTATCCAGGCTG-3P) and ACT2AS
(5P-CCGTGGTGGTGAAGCTGTAG-3P), located
within exon 3 of human L-actin gene, as an internal
control. Duplex PCR for DPC4 gene analysis in pan-
creas cell lines was achieved using primers
DPC4EX2S (5P-GGTCGTTTATTTTTCTAGGTG-
G-3P) and DPC4EX2AS (5P-CACTATTGAGAT-
CCTTTTCCCTTT-5P) located within exon 2, prim-
ers DPC4EX8S (5P-TGTTCTTTCCCATTTATT-
TCCT-3P) and DPC4EX8AS (5P-CTATACAAT-
CAATACCTTGCTCTCT-3P) located within exon
8, and primers for L-actin as well. PCR conditions
were as follows: 40 ampli¢cation cycles of denatur-
ation at 94‡C for 40 s, annealing at 63‡C for 30 s,
and extension at 72‡C for 30 s, followed by two
cycles at 63‡C for 2 min, and at 72‡C for 5 min.
Ampli¢cation products were loaded on a 12% native
polyacrylamide gel and visualized by ethidium bro-
mide staining. PCR reaction without DNA template
was performed as negative control.
2.6. RT-PCR analysis
Total RNA was treated with DNAse I (Promega)
as follows: 25 Wg of total RNA were incubated for
20 min at room temperature in 10 mM Tris^HCl pH
8.0, 20 mM MgCl2, 40 U of RNAsin and 4 U of
DNAse I. After two rounds of phenol/chloroform
(1:1) extraction and ethanol precipitation, RNA in-
tegrity was veri¢ed using 1% agarose gel electropho-
resis. cDNA was synthesized from 5 Wg of DNAse I-
treated total RNA with 500 ng oligo(dT)15 and 100
ng random hexamers (Promega), using 200 U of
MMLV-RT (BRL Life Technologies, Gaithersburg,
MD) in a 50-Wl reaction volume. For DCC mRNA
expression studies, PCR primers and conditions were
as described [20]. The expression of extracellular do-
main sequences was analyzed using the pair of prim-
ers DCK2834S (EX1) and DCK3151A (EX2) de-
scribed by Reale et al. [36], generating a PCR
product (EXTRA) of either 341 or 281 bp according
to alternative splicing. Expression of intracellular do-
main sequences was analyzed using the primers
DCK4540A (IN2), described by Reale et al. [36],
and IN3 (5P-CAA CGC TAG AAA GTC CCC
AGT A-3P), generating a PCR product (INTRA) of
either 164 or 159 bp in case of alternative splicing.
For DPC4 mRNA expression studies, a 285-bp frag-
ment was ampli¢ed using previously described prim-
ers located within exons 8 (sense) and 11 (antisense)
[37]. Ampli¢cation products were analyzed by 1.5%
agarose gel electrophoresis and visualized by ethid-
ium bromide staining. cDNA quality was tested for
each sample in an independent PCR reaction with
primers speci¢c for L-actin transcripts. The number
of cycles was optimized for each primer pair so that
ampli¢cations were in the linear range to ensure
semiquantitative measurements, as described earlier
[20]; 33 cycles were used for DCC, 30 cycles for
DPC4, and 16 cycles for L-actin. The relative expres-
sion levels of DCC and DPC4 mRNAs were assessed
by semiquantitative densitometry. The ratio of inte-
grated areas for DCC or DPC4, and L-actin PCR
products was calculated for each sample. Control
samples were included in all assays, as described in
more detail elsewhere [20].
2.7. cDNA sequencing analysis
DPC4 cDNA from pancreas cancer cell lines was
sequenced. A 699-bp fragment of the DPC4 cDNA
encompassing exons 8^11 was ampli¢ed from pan-
creas cancer cell lines using primers DPC4/ex.8S
(5P-CTCCTGAGTATTGGTGTTCC-3P) and DPC4/
ex.11AS (5P-CTAAAGGTTGTGGGTCTGC-3P).
This PCR product was visualized using 1.5% agarose
gel electrophoresis and ethidium bromide, puri¢ed
using the Wizard PCR preps puri¢cation system
(Promega) according to the manufacturer’s protocol,
BBADIS 61968 9-10-00
V.M. Barbera¤ et al. / Biochimica et Biophysica Acta 1502 (2000) 283^296286
and directly sequenced using the dRhodamine termi-
nator cycle sequencing kit (Perkin Elmer, Applied
Biosystems Division, Foster City, CA) in an ABI
Prism 310 DNA automated sequencer (Perkin Elmer,
Applied Biosystems Division). For each PCR prod-
uct, both strands were sequenced using the external
primers and two internal primers, DPC4/ex.10AS (5P-
GCTGCTGCATCTGTCGA-3P) and DPC4/ex.9S
[37].
3. Results
3.1. Microsatellite analysis
We have studied loss of heterozygosity (LOH) us-
ing microsatellite markers from the 18q21 region in
DNA from 12 colon cancer cell lines, 10 normal and
tumor paired samples from patients with colorectal
carcinoma, 16 pancreatic cancer cell lines derived
from ductal adenocarcinomas, and normal exocrine
pancreas cultures displaying a ductal phenotype. As
the corresponding normal DNA was only available
for two of the pancreatic cancer cell lines, the LOH
analysis was restricted to the comparison of the ob-
served heterozygous frequency with that expected ac-
cording to the data from the Genome Database
(www.gdb.org). Results are summarized in Table 1.
Homozygous deletions were not observed in any of
the lines. However, the frequency of heterozygosity
among colorectal cancer lines was lower than ex-
pected at all marker loci, except for D18S851.
Among pancreas cancer lines, observed heterozygos-
ity frequency was lower than expected at all sites
(Table 1). Fig. 1 shows representative results from
microsatellite analysis at the four loci for IMIM-
PC-2 and SK-PC-1 pancreas cell lines, for which
normal DNA was available. To extend these ¢nd-
ings, a panel of colorectal tumors was studied. Be-
cause homozygous deletions are generally di⁄cult to
detect in tissue samples due to contamination with
Fig. 1. Representative microsatellite analysis of DNA from
IMIM-PC-2 and SK-PC-1 pancreas cancer cell lines (T) and the
corresponding normal (N) DNA. Arrows indicate allelic losses
(LOH) for each marker indicated on the left.
Table 1
Summary of results from allelic deletion studies in colon and pancreatic cancer cell lines
Microsatellite marker
D18S877 D18S851 D18S858 D18S64
Expected heterozygosity frequencya 0.81 0.55 0.83 0.73
n Observed heterozygosity frequency
Colon cancer cell lines 12 0.33 0.67 0.17 0
Pancreatic cancer cell lines 16 0.06 0 0 0
There were no homozygous deletions at 18q21 in any of the colon or pancreas cancer cell lines analyzed.
aExpected heterozygosity frequency based on reported data from Genome Database (www.gdb.org).
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normal cells, tumor areas were selected for analysis
on the basis of a s 80% tumor cell content. This cut-
o¡ was selected on the basis of experiments showing
that LOH can be reproducibly detected in mixtures
of normal and cancer cells containing 60% or more
tumor cells (data not shown). All cases were infor-
mative for at least two markers. Apparent homozy-
gous losses, de¢ned on the basis of lack of ampli¢-
Fig. 2. Analysis of the 18q21 region in primary colorectal tumors. (A) Summary of the microsatellite study of four highly polymorphic
markers £anking DCC and DPC4 genes in 10 colorectal tumors. Only three cases (24, 96, 126) showed homozygous deletions at any
given marker. (B) Representative microsatellite analysis of DNA from normal (N) and tumor (T) samples from case 24 for each of
the markers indicated. (C) Duplex PCR analysis of DCC gene (exon 15) and L-actin in the 3 cases (24, 96 and 126) showing homozy-
gous deletions at D18S851 and/or D18S858 markers. PCR was performed on genomic DNA from normal (N) and tumor (T) samples
using both DCC and L-actin (as internal control) primers. Case 125 was used as positive control lacking homozygous deletions. Size
of products for DCC exon 15 and L-actin exon 3 were 149 and 217 bp, respectively.
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cation of sequences £anking microsatellite markers,
were found in 3/10 cases (Fig. 2A). In two of them
(cases 24 and 96), homozygous losses a¡ected only
one marker, while in case 126, two markers were
involved (Fig. 2B). As representative results, Fig.
2A shows the microsatellite analysis at the four loci
for case 24. Because these markers are in the vicinity
of DCC, we performed duplex PCR analysis on ge-
nomic DNA using primers from DCC and L-actin (as
an internal control) sequences. The results of this
study are shown in Fig. 2C: all three cases retained
DCC exon 15. We have not attempted to correlate
molecular ¢ndings with clinical data given the small
size of the samples analyzed.
3.2. DCC and DPC4 expression studies
We have previously shown that DCC transcripts
are detectable in normal colonic epithelium and in
the majority of colorectal cancer cell lines [20]. We
have extended these studies to the analysis of DPC4
expression using semiquantitative RT-PCR. As
shown in Fig. 3, DCC and DPC4 transcripts were
detected in 11/12 and 12/12 colorectal cell lines ex-
amined, respectively. However, the DCC/actin and
DPC4/actin mRNA ratios were lower in all cell lines
than in normal colon; this ¢nding may be explained
by allelic losses as suggested by the LOH analysis
described above. The size of the ampli¢cation prod-
Fig. 3. RT-PCR expression studies of DCC and DPC4 mRNAs in colon cancer cell lines. Left side: electrophoretic analysis of PCR
products from linear phase cDNA ampli¢cations. PCR results on normal colon mRNA are shown, as well as control reaction without
cDNA template (H2O). DCC cDNA EXTRA and INTRA ampli¢cations generated PCR fragments of 341 or 281 bp, and 164 or 159
bp, respectively, resulting from previously described alternative splicing. Asterisk shows the abnormally sized DPC4 PCR product de-
tected using SK-CO-20 cDNA. Arrow indicates the presence of an additional PCR product when using DPC4 primers. Right side: rel-
ative expression levels of DCC and DPC4 mRNAs assessed by semiquantitative densitometry (DCC or DPC4 density units/actin den-
sity units).
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ucts was as expected, except for a slightly larger
DPC4 product identi¢ed in SK-CO-20 cells. As in-
dicated in Fig. 4, DCC mRNA was detected in all 10
colorectal tumors analyzed, although a substantial
decrease was observed in tumor samples, compared
to the normal counterparts, in eight of the ten cases
studied. Regarding DPC4, transcripts were detected
in all samples though, in seven cases, relative levels
were at least 40% lower in the tumor.
Because there is little information on the expres-
sion of DCC and DPC4 in normal pancreatic ducts,
we used RT-PCR to detect their transcripts in nor-
mal pancreatic cultures displaying a ductal pheno-
type [33]. As shown in Fig. 5, DCC and DPC4 tran-
scripts, as well as L-actin transcripts analyzed as a
control, were present in normal cultures. Fig. 6
shows the results of semiquantitative PCR analysis
of DCC and DPC4 mRNAs in pancreas cancer cell
lines. In 7/16 (44%) cell lines, no products were am-
pli¢ed using primers corresponding to both extracel-
lular and intracellular domains of DCC; in an addi-
tional four lines, low levels of ampli¢cation were
achieved only with primers corresponding to the in-
tracellular domain. Such discrepancy between the
ampli¢cation of sequences corresponding to di¡erent
exons of DCC in its mRNA has previously been
described by us and others [14,20]. DPC4 transcripts
were undetectable in 5/16 (31%) cell lines and an
abnormally sized PCR product was identi¢ed in
MZPC-1 cells. Therefore, the low levels of DCC
and DPC4 transcripts found in pancreas cancer cell
lines do represent an abnormal ¢nding.
Fig. 4. RT-PCR expression studies of DCC and DPC4 mRNAs in primary colorectal tumors. Left side: electrophoretic analysis of
PCR products from linear phase cDNA ampli¢cations. For each tumor sample, PCR results on its normal colon mRNA counterpart
are shown, as well as control reaction without cDNA template (H2O). Sizes of DCC PCR fragments are as described in Fig. 3. Right
side: relative expression levels of DCC and DPC4 mRNAs assessed by semiquantitative densitometry (DCC or DPC4 density units/ac-
tin density units).
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Alterations in DCC and DPC4 expression in colo-
rectal and pancreatic cancers occurred independ-
ently: in 2/3 colorectal cancer cell lines showing
DPC4/actin mRNA ratios similar to those of normal
colon, the levels of DCC/actin mRNA ratios were
low and similar discordances were observed when
comparing the paired samples of normal and tumoral
tissue from the same patient. The ¢ndings among
pancreas cancer cell lines were even more striking:
for example, high levels of DCC transcripts were
detected in CFPAC1 cells in the absence of DPC4
transcripts and the reverse was observed for other
lines such as Capan-1, SK-PC-3, RWP-2, and MIA
PaCa-2 (Fig. 6).
3.3. DPC4 gene status and sequencing in pancreas
cancer cell lines
DPC4 transcripts were undetectable in 5/16 cell
lines in which homozygous deletions had not been
identi¢ed using microsatellite markers. To examine
the DPC4 gene status, a duplex PCR on genomic
DNA for individual DPC4 exons (2 and 8) and L-
actin exon 3 (as internal control) was performed. In
all ¢ve cases, the DPC4 genomic sequences were not
ampli¢ed, implying the homozygous loss of DPC4
gene. Representative examples for exon 2, including
control cell lines in which DPC4 transcripts were
detected, are shown in Fig. 7A. DPC4 exons 8^11
and their £anking sequences were analyzed because
more than 80% of the mutations have been found in
this region of the gene [22,25,26,28,38,39]. Direct se-
quencing of both strands of PCR products from the
11 cell lines with detectable levels of DPC4 mRNA
yielded abnormal sequences only in three of them:
MZPC-1, MZPC-2 and SK-PC-3. In MZPC-1, the
sequencing con¢rmed that the larger size of the
PCR product obtained was due to a 117-bp insertion
between exons 10 and 11 (Fig. 7B). Comparison of
this sequence with data banks did not yield any sig-
ni¢cant matches. However, as we found a stop codon
in frame with exon 10 coding sequence, it is predicted
that a truncated DPC4 protein is synthesized in these
cells. As shown in Fig. 7B, the sequence of DPC4
transcripts from the other two cell lines contained
point mutations, leading to non-conservative amino
acid substitutions (D351H and I383K, respectively).
In two additional lines (Capan-2, IMIM-PC-2),
DPC4 exons 2 and 8 were not a¡ected by homozy-
gous deletions as observed by duplex PCR (Fig. 7A),
DPC4 transcripts were detected (Fig. 6), no muta-
tions were found in coding sequences from exons
8^11, but no protein was detected by Western blot-
ting (data not shown). In the remaining 6 cell lines,
no abnormalities were detected in the gene or protein
using the assays described above.
4. Discussion
Detection of allelic losses at 18q21 by microsatel-
lite analysis has been widely applied as an approach
to evaluate the implication of tumor suppressor
genes located in this region in gastrointestinal neo-
plasms. When highly polymorphic markers are used,
this approach e⁄ciently allows detection of loss of
heterozygosity at marker loci. Nevertheless, it does
not provide direct information on tumor suppressor
gene loss and it is not commonly used to analyze
homozygous losses as the presence of contaminating
normal cells hinders interpretation of results. In this
work, by using four microsatellite markers and a
panel of cell lines and selected colorectal cancer tis-
sues containing a very high density of tumor cells, we
demonstrate that this approach presents limitations
that may explain con£icting published results on the
Fig. 5. RT-PCR expression studies of DCC and DPC4 mRNAs
in primary cultures of normal exocrine pancreas (day 5). Elec-
trophoretic analysis of PCR products from cDNA ampli¢cation
is shown. PCR reactions using cDNA from Capan-2 pancreas
cancer cells as well as a mixture without template (H2O) were
included as controls.
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occurrence and signi¢cance of losses of tumor sup-
pressor genes at 18q21 (as discussed in [13]).
We have found that there were no homozygous
losses for any of these markers in any of the colo-
rectal and pancreatic cancer cell lines analyzed. Con-
sistent with these ¢ndings is the retention of DCC
and DPC4 transcripts in the majority of colorectal
cell lines studied, the only exception being the lack of
DCC mRNA in one cell line. Other investigators
have also proposed that DCC inactivation in colo-
rectal cancer would occur by mechanisms independ-
ent of allelic loss [12,14]. Regarding DPC4, our re-
sults are in general agreement with the low incidence
of alterations in colorectal tumors reported in other
studies [14,26,28,40]. While DPC4 inactivation can
stimulate the progression of adenomas to invasive
carcinomas in the Apcv716 mouse model [41], its
role in human colorectal cancer is less well estab-
lished [14,28]. Consistent with our data using cell
lines, only 3/10 cases of paired normal colon and
primary colorectal tumors presented homozygous
losses at any of the markers. In these 3 cases, DCC
exon 15 was not lost, based on duplex PCR analysis.
Because tumor areas containing a very high propor-
tion of neoplastic cells were selected and the quality
of DNA was assessed, it is highly unlikely that these
results represent possible contamination by normal
stromal cells. Therefore, homozygous losses in this
Fig. 6. RT-PCR expression studies of DCC and DPC4 mRNAs in pancreas cancer cell lines. Left side: electrophoretic analysis of
PCR products from linear phase cDNA ampli¢cations. Arrowhead indicates the abnormally sized DPC4 PCR product detected using
MZPC-1 cDNA. Control reaction without cDNA template (H2O) is shown. Sizes of DCC PCR fragments are as described in Fig. 3.
Arrow indicates the presence of an additional PCR product when using DPC4 primers. Right side: relative expression levels of DCC
and DPC4 mRNAs assessed by semiquantitative densitometry (DCC or DPC4 density units/actin density units).
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region appear to be an uncommon mechanism of
inactivation of tumor suppressor genes in colorectal
cancer. In particular, as it refers to DCC, allelic de-
letions in up to 70% of colorectal tumors and cell
lines and a limited number of somatically acquired
mutations have been reported [16,42^45]. We cannot
exclude the possibility that DCC and DPC4 might be
lost more frequently in more advanced steps of car-
cinogenesis, but our data indicate that microsatellite
analysis does not reliably identify the loss of tumor
suppressor genes. This conclusion is also supported
by our results in pancreas cancer cell lines. Despite
that no homozygous losses at 18q21 were detected
using microsatellite markers, DPC4 was inactivated
by homozygous deletions in 5/16 cell lines. This ob-
servation is in general agreement with the reported
deletion rate [22,46]. More work is necessary to es-
tablish the rate of homozygous losses using primary
pancreas cancer tissues and careful microdissection
analysis (i.e. laser capture microdissection) because
of the strong desmoplastic and in£ammatory reac-
tion that often accompanies these tumors.
Among pancreas cancer cell lines, two additional
mechanisms of DPC4 gene inactivation were identi-
¢ed in our study. Mutations in exons 8^11 were
present in 3/16 cell lines, consistent with previous
work [22,25]; in these three cases, mRNA and pro-
tein were detected by RT-PCR and Western blotting,
respectively, and the apparent size of the protein was
normal (data not shown). In an additional two cases,
Fig. 7. DPC4 analysis in pancreatic cell lines. (A) Duplex PCR on genomic DNA for DPC4 exon 2 and L-actin exon 3 (as internal
control). Homozygous deletions of DPC4 exon 2 were observed in the ¢ve pancreatic cancer cell lines lacking detectable levels of
DPC4 transcripts (SK-PC-1, Hs766T, RWP-1, AsPC-1 and CFPAC-1); DPC4 exon 2 was ampli¢ed in two lines in which both
mRNA and protein were detected (SK-PC-3 and MZPC-2), as well as in one line in which mRNA was present, but no DPC4 protein
was detected (IMIM-PC-2). Size of PCR products for DPC4 exon 2 and L-actin exon 3 were 247 and 217 bp, respectively. (B) Se-
quence analysis of DPC4 cDNA (exons 8^11). Double strand sequencing was performed as described in Section 2. Non-conservative
point mutations identi¢ed in MZPC-2 and SK-PC-3 and leading to amino acid substitutions (D351H and I383K, respectively) are
shown (arrows indicate the mutated nucleotide, underlined in the above linear sequence). The 117 bp insertion between exons 10 and
11 found in MZPC-1 is represented.
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transcripts were present, but no protein was detected
by Western blotting (data not shown). The molecular
basis of lack of DPC4 protein in these cells has to be
investigated in greater detail ; one possibility is the
occurrence of mutations in other exons, as described
by Schutte et al. for exons 2 and 4 [25], leading to
misfolded unstable proteins that are rapidly de-
graded, or to conformational variants and truncated
proteins that are not recognized by the antibody used
in our study. Until now, there is no evidence for the
latter. In any case, a total of 10/16 cases showed
alterations in DPC4 gene or protein, supporting a
high rate of inactivation in this tumor. Recent data
from FISH analysis demonstrated that loss of 18q
chromosome would be an early event in pancreatic
ductal carcinogenesis [47]. The development of a
panel of antibodies recognizing various domains of
DPC4 would be useful and their application using
immunohistochemistry should contribute to the
study of pancreas cancer and its preneoplastic lesions
as lack of protein seems to account for the majority
of cases in which this gene is inactivated.
Regarding DCC in pancreas cancer, our results
show that DCC is expressed in normal ductal cells
in culture and its loss in tumor cell lines is in agree-
ment with prior reports [48,49]; however, the de-
tailed mechanisms leading to such loss were not ex-
amined due to the length and complex structure of
this gene which has hampered detailed mutational
analysis. The low levels of expression of DCC and
the con£icting results from DCC gene product ana-
lyzes [50^52] also precluded the use of Western blot-
ting as a reliable strategy to detect lack of protein in
tumor cells. Using orthotopically implanted human
pancreatic tumors as a model system, a reduction or
loss in the levels of DCC mRNA has recently been
shown to be restricted to metastatic lesions [28]. As
cancer cell lines often accumulate genetic alterations
that are associated with tumor progression in vivo,
our ¢ndings are in agreement with the contention
that DCC expression may be lost at late stages of
pancreas cancer progression. The ¢nding that alter-
ations in DCC and DPC4 occur independently both
in colorectal and pancreatic cancer is also in agree-
ment with the study of xenografts of these tumor
types in mice [28].
In conclusion, our work supports the involvement
of the 18q21 region both in colorectal and in pancre-
atic cancer. However, our ¢ndings indicate that it is
di⁄cult to draw conclusions about the role of tumor
suppressor genes in this region from the majority of
published studies: homozygous losses detected using
microsatellite analysis do not imply loss of the rele-
vant cancer genes and lack of homozygous losses
does not ensure retention of at least one allele. As
suggested in a recent Editorial [13], the clari¢cation
of the role of tumor suppressor genes at 18q21 in
cancer will require the study of ‘gene-speci¢c molec-
ular markers’ rather than surrogate microsatellite
markers.
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